Manufacturer temporarily suspends marketing of Trasylol in Canada - Consumer InformationHealth Canada has requested that Bayer Inc., maker of Trasylol, temporarily suspend sales of Trasylol (aprotinin) until a review is completed of results from the BART study. The BART study indicated an increased risk of death form use of Trasylol. Bayer Inc. is to help Health Canada provide the drug to certain patients in cases where the doctor believes the potential benefit clearly outweighs the risk.
Trasylol, used by injection during heart bypass surgery, reduces bleeding. Health Canada's review of post market safety information for Trasylol has led to this action.
Bayer Inc. has recently sent a notice to hospitals and physicians regarding the suspension of the BART study. Health Canada will continue to communicate information and recommendations related to this product to health professionals and the public.
Health Canada informed health care professionals about safety information for Trasylol on March 27, 2007 and on February 28, 2006.
